|
Giant Biogene Holding Co., Ltd is a biotechnology company focused on recombinant collagen research, development, and commercialization. The company operates in the medical device and professional skincare sectors, offering products such as Recombinant Type I α1 Subtype Collagen Freeze-dried Fibers and Recombinant Type I α1 Subtype Collagen and Sodium Hyaluronate Composite Solution. Its brand portfolio includes KOMFYMED, which focuses on professional skincare, Collgene, which emphasizes self-acceptance and recombinant technology, and Ke Yu, which integrates health protection into daily life. Giant Biogene serves both medical professionals and mass consumers through an omni-channel network that includes direct sales, offline brand experience stores, and retail partners such as Sephora and China Duty Free Group. The company markets its products in China and internationally across North America, Southeast Asia, and East Asia. It maintains a significant research pipeline with over 140 projects and holds numerous patents, participating in the drafting of industry standards for recombinant collagen dressings. Summarised from the company's own disclosures, fiscal year ended Apr 2026 |
Industry Biotechnology | Homepage xajuzi.com |
| Sector Healthcare | IR page ir.xajuzi.com | |
|
Tags
recombinant collagen, medical devices, professional skincare, cosmetics, biomanufacturing, dermatology, consumer health, KOMFYMED, Collgene, Ke Yu, Recombinant Type I α1 Subtype Collagen Freeze-dried Fibers, Recombinant Type I α1 Subtype Collagen and Sodium Hyaluronate Composite Solution
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | HK$ 20.01B |
| Market cap (USD) | $ 2.55B |
| P/E | 9.14 |
| PEG | 0.38 |
| P/BV | 1.81 |
| P/S | 3.19 |
| P/OCF | 9.17 |
| P/FCF | — |
| Dividend yield | 7.4% |
| Turnover / mcap | 0.34% |
| Returns | |
|---|---|
| ROE | 22.5% |
| ROI | 19.3% |
| ROIC | 19.3% |
| Profit margin | 34.7% |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | — |
| Earnings growth 3y (net profit CAGR) | 24.1% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | -6.3% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpAnnouncements and reports published on HKEXnews, newest first, monthly and next-day returns, proxy forms and board-meeting notices included. The link opens the announcement on HKEXnews. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Giant Biogene Holding Co., Ltd
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.









陕公网安备61019002001928号 互联网药品信息服务证书:(陕)-非经营性-2024-0034



